Published • loading... • Updated
NICE backs atogepant for acute migraine treatment - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
NICE backs atogepant for acute migraine treatment - Pharmafile
NICE has issued Final Draft Guidance recommending AbbVie’s AQUIPTA (atogepant) as an option for the acute treatment of migraine, with or without aura, in adults who have not responded adequately to at least two triptans or who cannot take them. The recommendation also applies to patients whose migraines have not been adequately controlled with non-steroidal […] The post NICE backs atogepant for acute migraine treatment appeared first on Pharmafi…
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
